Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci

Blood (2014) 124 (21): 3485.

https://doi.org/10.1182/blood.V124.21.3485.3485

Published: 2014

Journal Articles

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

Eileen M Boyle, MD, Brian A Walker, PhD, Dorota Rowczienio, MSc, Christopher P Wardell, PhD, Alexander Murison, PhD, Aneta Mikulasova, M.Sc., Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Anna Baginska, Shameem Mahmood, MRCP. FRCPath, Julian D Gillmore, Helen J Lachmann, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci, Xavier Leleu, MD PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Ashutosh Wechalekar, MDFRCPath

Blood (2014) 124 (21): 726.

https://doi.org/10.1182/blood.V124.21.726.726

Published: 2014

Journal Articles

Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD)

Kate Stringaris, MBBS, MRCP, FRCPath, PhD, Rabya Sayed, MRCP, Helen J Lachmann, MD FRCP, Julian D Gillmore, Philip N Hawkins, Ashutosh Wechelaker, MDMRCP FRCPath

Blood (2014) 124 (21): 1198.

https://doi.org/10.1182/blood.V124.21.1198.1198

Published: 2014

Journal Articles

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Ruth M de Tute, Anna Baginska, Christopher Parrish, MD, Shameem Mahmood, MRCP. FRCPath, Andy Rawstron, PhD, Julian D Gillmore, MD FRCP, Helen J Lachmann, MD FRCP, Philip N Hawkins, Roger G Owen, MD, Ashutosh Wechalekar, Dr

Blood (2014) 124 (21): 2073.

https://doi.org/10.1182/blood.V124.21.2073.2073

Published: 2014

Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3143.

https://doi.org/10.1182/blood.V122.21.3143.3143

Published: 2013

Journal Articles

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Brian A Walker, PhD, Dorota Rowczienio, MSc, Eileen M Boyle, MD, Christopher P Wardell, PhD, Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Julian D Gillmore, MD, Shameem Mahmood, MRCP. FRCPath, Helen J Lachmann, MD, FRCP, Philip N Hawkins, Faith E Davies, MD, Gareth J Morgan, MD PhD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 3098.

https://doi.org/10.1182/blood.V122.21.3098.3098

Published: 2013

Journal Articles

Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis

Murielle Roussel, MD, Giovanni Palladini, Simon DJ Gibbs, Christopher P. Venner, MD, Jean-Paul Fermand, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Giampaolo Merlini, Arnaud Jaccard, Ashutosh Wechalekar, MD

Blood (2012) 120 (21): 4074.

https://doi.org/10.1182/blood.V120.21.4074.4074

Published: 2012

Journal Articles

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Shameem Mahmood, MBBCh. FRCPath, Christopher P. Venner, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2012) 120 (21): 2978.

https://doi.org/10.1182/blood.V120.21.2978.2978

Published: 2012

Journal Articles

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Helen J Lachmann, MD, FRCP, Stephen Harding, PhD, Ashutosh Wechalekar, MD, FRCPath, Julian D Gillmore, E. Nicole Amft, MD, PhD, FRCP, Philip N Hawkins

Blood (2010) 116 (21): 3958.

https://doi.org/10.1182/blood.V116.21.3958.3958

Published: 2010

Journal Articles

Abnormal NT-ProBNP in AL Amyloidosis Patients without Cardiac Involvement at Diagnosis - A Predictor of Subsequent Cardiac Involvement.

Ashutosh D. Wechalekar, MD, Helen J. Lachmann, MD, Julian D. Gillmore, MD, PhD, Philip N. Hawkins, PhD, FRCP

Blood (2007) 110 (11): 1500.

https://doi.org/10.1182/blood.V110.11.1500.1500

Published: 2007

Journal Articles

A Profile of 44 Long Term Survivors (>10yrs) with AL Amyloidosis.

Ashutosh D. Wechalekar, MD, Helen J. Lachmann, MD, Julian D. Gillmore, MD, PhD, Philip N. Hawkins, PhD, FRCP

Blood (2007) 110 (11): 4765.

https://doi.org/10.1182/blood.V110.11.4765.4765

Published: 2007

Journal Articles

Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.

Hugh J.B. Goodman, FRACP FRCPA, Helen J. Lachmann, MD MRCP, Arthur R. Bradwell, FRCP FRCPath, Philip N. Hawkins, PhD FRCP

Blood (2004) 104 (11): 755.

https://doi.org/10.1182/blood.V104.11.755.755

Published: 2004

NARROW

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD)

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Abnormal NT-ProBNP in AL Amyloidosis Patients without Cardiac Involvement at Diagnosis - A Predictor of Subsequent Cardiac Involvement.

A Profile of 44 Long Term Survivors (>10yrs) with AL Amyloidosis.

Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only